§ 99.405. Applicability of labeling, adulteration, and misbranding authority.
118 words·~1 min read·
/us/cfr/t21/s§ 99.405·A research copy — for the controlling text, always check the official state or federal source. Not legal advice.
The dissemination of information relating to a new use for a drug or device may constitute labeling, evidence of a new intended use, adulteration, or misbranding of the drug or device if such dissemination fails to comply with section 551 of the Federal Food, Drug, and Cosmetic Act (the act) (21 U.S.C. 360aaa) and the requirements of this part. A manufacturer's failure to exercise due diligence in submitting the clinical studies that are necessary for the approval of a new use that is the subject of information disseminated under this part or in beginning or completing such clinical studies shall be deemed a failure to comply with section 551 of the act and the requirements of this part.
Connections1 off-index
1 reference not yet in our index
- 21 USC 360aaa
Citation graph
cites case law
§ 99.405
Applicability of labeling, adulteration, and misbranding authority.
Cite21 USC 360aaa
Cites 1Cited by 0 across 0 sources